Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

The energy-intensive plant would nearly double U.S. aluminum production, though questions remain on how much of its power ...

The CFO of the Year Awards recognize the trailblazing financial leaders who navigate complex challenges, fuel growth, and ...